Clinical Trials Browser

Phase 1/2 × monoclonal antibody YYB-101 × Clear all

NCT04368507 2022-11-14

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

Phase 1/2 Completed

Gastrointestinal

Colorectal Cancer Metastatic